FP7Individual fellowship2009–2011

AXOGLIA · Understanding the axon-glial functional unit in myelination and remyelination

FP7 — People (Marie Curie Actions)

Duration
2009-03-01 → 2011-07-31
EU contribution
€148,616
Participants
1
Scheme
MC-IEF

Lines connect the coordinator with its partners.

Results in brief

Understanding the axon-glial functional unit in myelination and remyelination

Myelination of nerve fibres by glial cells, oligodendrocytes in the central nervous system (CNS) and Schwann cells in the peripheral nervous system (PNS), gives rise to the axon/glia functional unit with its unique properties, e.g. axon protection, and increased resistance and decreased capacitance across large calibre axons for fast saltatory conduction of action potentials. The importance of the myelination process is highlighted by the fact that loss or damage of myelin is one of the major mechanisms underlying the pathology of devastating neurological disorders including leukodystrophies, central and peripheral neuropathies, and inflammatory demyelinating diseases such as multiple sclerosis (MS). These diseases present a high incidence, severe symptoms and a poor treatment outcome. Thus, they represent a serious health as well as economic and social burden at European level (Gustavsson et al., 2011). Remyelination, the process by which demyelinated axons are reinvested with new myelin sheath following demyelination, is required to ensure recovery of physiological activity of the nerves (Bruce et al., 2007). Spontaneous remyelination in human demyelinating diseases can occur, but it is an uneven process often insufficient to preserve axon integrity and, ultimately, proper physiological activity. It is possible that during demyelination and remyelination expression of key signaling molecules is altered. Long-term axon protection could therefore be achieved only through the re-establishment of an efficient axon/myelin functional unit cross-talk. According to this hypothesis, only a “correct” remyelination consisting in the preservation of the original axonal and myelin expressed proteome could potentially reduce axonal loss. Over the past few years it has been realized that the interaction of myelinating glia with axons is bidirectional and recent data suggest that the myelinating glia plays an active role in the maintenance of axon integrity, whose preservation could be the key to prevent chronic progressive disability (Edgar and Garbern, 2004; Lubetzki et al., 2005; Zawadzka and Franklin, 2007). Despite the importance of these processes, no clear understanding of the key molecules and signalling pathways involved and altered in demyelination and remyelination is presently available (Bruce et al., 2007). Our lack of a clear understanding of the general mechanisms underlying myelination and remyelination arises in part from the fact that most of the studies have been relying on conventional molecular, biochemical and cellular methodologies which permit to successfully address one or a few identified molecules of interest but cannot provide a complete profile of the complex events underlying these processes. This fellowship aimed to combine this classical approach to systems biology approach. Conventional molecular, biochemical and cellular methodologies have been applied to study a previously identified interesting candidate (i.e. Profilin 1, see 1 below) for its role in PNS and CNS myelination. A system biology approach has been applied to identify new potential candidates likely to play a role in CNS myelination/remyelination (or its failure) (see 2 below).

Data: CORDIS, © European Union

Project objective

Loss or damage of myelin is one of the major mechanisms underlying the pathology of several neurological disorders, e.g. leukodystrophies, central and peripheral neuropathies, and inflammatory demyelinating diseases such as multiple sclerosis (MS), a serious health as well as economic and social burden at European level. Remyelination, the process by which demyelinated axons are reinvested with new myelin sheath, is required to ensure recovery of physiological activity of the nerves. Even if spontaneous remyelination in human demyelinating diseases can occur, it is an uneven process often insufficient to preserve axon integrity. Long-term axon protection could be achieved through the re-establishment of an efficient axon/myelin functional unit. Only a “correct” remyelination consisting in the preservation of the original axonal and myelin expressed proteome could potentially reduce axonal loss. No clear understanding of the key molecules involved in myelination and remyelination is at the moment available. Conventional molecular and cell biological assays do not provide a complete profile of the molecular changes involved in the establishment and maintenance of the myelin sheath. The fellow will apply a multidisciplinary approach. Forefront proteomics techniques (iTRAQ) will allow to profile the membrane proteins present at the axon/myelin interface and involved in initiating and maintaining myelination. The fellow will also address how remyelination, in a demyelinating animal model, differs from developmental myelination. The localization and specific function of a subset of interesting candidates will be analyzed in vitro and in vivo, in order to broaden our knowledge of the basic molecular processes underlying myelination/remyelination and to identify potential therapeutical targets. The fellowship will help Europe to become more prominent in the area of Systems biology, in which North America is at the moment leading, and strengthen European collaborations.

Original text from CORDIS.

Participants

  • INSTITUTO DE BIOLOGIA MOLECULAR E CELULAR-IBMC · PortoCoordinatorPortugal

Links

Data: CORDIS, © European Union